Tuesday, April 3, 2018

BRIEF-‍European Commission Approves Expanded Indication For Amgen's Xgeva

* ‍EUROPEAN COMMISSION APPROVES EXPANDED INDICATION FOR AMGEN'S XGEVA (DENOSUMAB) FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH MULTIPLE MYELOMA​ Source text for Eikon: Further company coverage:
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)